Topical Antifungal Therapy in COVID Associated Mucormycosis: A new hope?
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/10/037257
- Lead Sponsor
- Dr Zaid Shaikh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 45
Inclusion Criteria
Patients were microbiologically and histologically proven cases of mucormycosis and underwent open or endoscopic surgical debridement for Mucormycosis. Patients must have received a minimum of three weeks of systemic Amphotericin B administration postoperatively without any discontinuity
Exclusion Criteria
Patients having mandibular or disseminated forms of mucormycosis, where study participants refused giving prior consent of participation. Patients who were deceased before three weeks or had interruption in treatment with systemic Amphotericin B
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome is to assess the number of patients requiring revision surgery for mucormycosis residual/recurrenceTimepoint: Postoperative day 7, 14 and 21 evaluation
- Secondary Outcome Measures
Name Time Method AIIMS Bhubaneswar Mucormycosis Endoscopic Scoring System (AMESS) and its association with Revision surgeryTimepoint: Within 21 days of primary surgery